Biotech - Spark Newswire

1 minute read

Seres Therapeutics’s Phase 3 Ecospor IV Trial Data SER-109 To Prevent Recurrent C. Difficile Infection Is Published In Jama Network Open

Today, 3:12 AM

Clinical data show that 91.3% of subjects remained free of C. difficile infection recurrence at 8 weeks, supporting and extending previous Phase 3 study results.

MCRB

1 minute read

Gritstone bio And The National Cancer Institute Establish Clinical Trial Agreement To Evaluate A Neoantigen Cell Therapy-Vaccine Combination

By Bill Haddad

Today, 3:12 AM

Under the terms of the agreement, NCI will identify patients with metastatic cancer that are eligible for adoptive cell transfer based on the presence of a G12V or G12D KRAS mutation (KRASmut). Gritstone will provide the

GRTS

1 minute read

Verve Therapeutics Announced VERVE-101 Awarded Innovation Passport By UK MHRA For Treatment Of Heterozygous Familial Hypercholesterolemia

By Charles Gross

Today, 3:12 AM

Verve Therapeutics, Inc. today announced that VERVE-101 has been awarded the Innovation Passport for the treatment of heterozygous familial hypercholesterolemia (HeFH) under the Innovative Licensing and Access Pathway (ILAP) by the Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory body of the United Kingdom (UK).

VERV

3 minute read

Cullinan Oncology Licenses U.S. Rights To The First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator From Harbour BioMed; Currently In A Phase 1 Clinical Study Being Conducted At U.s. And Australian Sites In Patients With Advanced Solid Tumors

By Happy Mohamed

Today, 3:12 AM

Cullinan Oncology, Inc. (NASDAQ:CGEM) and Harbour BioMed (HKEX: 02142) today announced that Cullinan Oncology has entered into an exclusive license with Harbour BioMed for the development and

CGEM

5 minute read

Opdivo In Combination With CABOMETYX Shows Durable Survival With Over Three Years Of Follow-Up In The CheckMate -9ER Trial In First-Line Advanced Renal Cell Carcinoma

By Happy Mohamed

Today, 3:12 AM

Data to be featured at ASCO GU 2023 demonstrate continued overall survival, progression-free survival and objective response rate benefits with Opdivo in combination with CABOMETYX compared to

BMY

1 minute read

FDA
News

MacroGenics Highlights Preliminary Clinical Results From Single Arm Study Of Lorigerlimab

By Benzinga Newsdesk

Today, 3:12 AM

Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved

MGNX

1 minute read

FDA
News

Aravive To Present Updated Data From Phase 1b Trial Of Batiraxcept

By Benzinga Newsdesk

Today, 3:12 AM

ravive, Inc. (NASDAQ:ARAV, ", the Company", )))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its

ARAV

2 minute read

Joint Statement By Sorrento Therapeutics, Inc. And Scilex Holding Company On Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.

By Happy Mohamed

Today, 3:12 AM

Scilex Holding Company (NASDAQ:SCLX, ", Scilex", )))), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )))) and an innovative revenue-generating company focused on

SCLX